AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12492188
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules p.o. b.i.d. for 6 weeks
Trial: 2695806
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg telenzepine once daily
Trial: 2695806
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg telenzepine once daily
Trial: 2695806
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg telenzepine once daily
Trial: 2695806
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg and 3 mg telenzepine
Trial: 11986476
Drug: Long-course antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-course antibiotic therapy (7-14 days)
Trial: 30952565
Drug: Integrated care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated care centres providing HIV testing, prevention, and treatment services.
Trial: 28592250
Drug: Mass Testing
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass Testing and Treatment (MTaT) approach
Trial: 10517908
Drug: 2% diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% diltiazem gel
Trial: 19768381
Drug: Sequential intravenous/oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential intravenous/oral moxifloxacin, 400 mg once daily for 7-21 days
Trial: 19768381
Drug: Intravenous amoxicillin/clavulanate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amoxicillin/clavulanate, 1,000 mg/200 mg three times daily followed by oral amoxicillin/clavulanate, 500 mg/125 mg three times daily for 7-21 days
Trial: 16229991
Drug: Sequential intravenous/oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential intravenous/oral moxifloxacin
Trial: 19768381
Drug: Intravenous amoxicillin/clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amoxicillin/clavulanate followed by oral amoxicillin/clavulanate
Trial: 18268075
Drug: Ramipril (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (15 mg/day)
Trial: 9692107
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids treatment for 3 years
Trial: 2848902
Drug: Human-rhesus reassortant
RxNorm normalized name: human-bovine reassortant rotavirus strain G4 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human-rhesus reassortant rotavirus vaccines (serotypes 1, 2, or 4)
Trial: 2848902
Drug: Human-rhesus reassortant
RxNorm normalized name: human-bovine reassortant rotavirus strain G4 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human-rhesus reassortant rotavirus vaccines (serotype 2)
Trial: 2848902
Drug: Human-rhesus reassortant
RxNorm normalized name: human-bovine reassortant rotavirus strain G4 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human-rhesus reassortant rotavirus vaccines
Trial: 21145807
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ribavirin/day
Trial: 21145807
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg ribavirin/day
Trial: 21145807
Drug: peginterferon alfa-2a/ribavirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon alfa-2a/ribavirin treatment
Trial: 15215811
Drug: Pravastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (20 to 40 mg)
Trial: 9292674
Drug: Subconjunctival cefuroxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival cefuroxime not administered (n=9)
Trial: 3111689
Drug: Elantan Long
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elantan Long (50 mg IS 5‐MN) daily for 12 months
Trial: 27821027
Drug: Weekly intralesional
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly intralesional triamcinolone injections
Trial: 27821027
Drug: Biweekly intralesional
RxNorm normalized name: Biweekly Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biweekly intralesional triamcinolone injections
Trial: 22327761
Drug: Xylitol (chewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol (chewing gum for mothers and chewable tablets for children, 3 times a day for 3 months)
Trial: 19404314
Drug: Nebivolol 20
RxNorm normalized name: nebivolol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 20 mg
Trial: 20162736
Drug: Nebivolol 5-20
RxNorm normalized name: nebivolol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 5-20 mg
Trial: 12523328
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g rectal paracetamol
Trial: 12523328
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg x kg(‐1) rectal paracetamol
Trial: 1535579
Drug: Clarithromycin 250
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg
Trial: 9798808
Drug: Amoxycillin 1
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 1 g
Trial: 7900626
Drug: Sotalol 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol 1.0 mg/kg
Trial: 7900626
Drug: Sotalol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol 1.5 mg/kg
Trial: 7900626
Drug: Sotalol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol 1.5 mg/kg (open-label phase)
Trial: 7900626
Drug: Sotalol 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol 1.0 mg/kg (AF group)
Trial: 7900626
Drug: Sotalol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol 1.5 mg/kg (AF group)
Trial: 7900626
Drug: Sotalol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol 1.5 mg/kg (open-label phase, AF group)
Trial: 2527133
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily insulin injections (three preprandial injections of short‐acting insulin (NovoPen) and once daily, bedtime extended‐acting insulin)
Trial: 2527678
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily insulin injections (NovoPen)
Trial: 781234
Drug: Fenoprofen, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoprofen, 200 to 600 mg every six hours
Trial: 781234
Drug: Aspirin, 325
RxNorm normalized name: Aspirin, 325 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 325 to 975 mg every six hours
Trial: 31647605
Drug: Intravenous iscalimab
RxNorm normalized name: Iscalimab
DrugBank: Iscalimab (DB15260)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iscalimab (0.03, 0.1, 0.3, 1, or 3 mg/kg)
Trial: 31647605
Drug: Intravenous iscalimab
RxNorm normalized name: Iscalimab
DrugBank: Iscalimab (DB15260)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iscalimab (10 or 30 mg/kg)
Trial: 31647605
Drug: Intravenous iscalimab
RxNorm normalized name: Iscalimab
DrugBank: Iscalimab (DB15260)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iscalimab (3 mg/kg)
Trial: 31647605
Drug: Intravenous iscalimab
RxNorm normalized name: Iscalimab
DrugBank: Iscalimab (DB15260)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iscalimab
Trial: 29800080
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment (weekly lifestyle counseling and meal replacement diet)
Trial: 26044516
Drug: Probiotic group
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic group (2 g of powder containing 5 × 10^9 cfu of L. curvatus HY7601 and 5 × 10^9 cfu of L. plantarum KY1032 daily)
Trial: 16960523
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg of soybean‐derived phosphatidylserine (S‐PtdSer), administered daily for 7 days prior to exercise and for 2 days following exercise
Trial: 29652792
Drug: Blue mussel
RxNorm normalized name: Blue mussel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blue mussel diet (75 g blue mussels, five days a week)
Trial: 29652792
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (75 g meat, five days a week)
Trial: 27256357
Drug: ebselen (3600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ebselen (3600 mg over 24 h)
Trial: 25518523
Drug: L-carnitine (Elkar,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (Elkar, PikFarma)
Trial: 22858387
Drug: Sertraline (50-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50-200 mg/day for 4 months)
Trial: 21184675
Drug: TPN with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPN with daily glutamine supplement of 0.35 g/kg
Trial: 18702333
Drug: peg‐IFN‐alpha/RBV treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peg‐IFN‐alpha/RBV treatment (n = 18 with 2a, n = 9 with 2b)
Trial: 18702333
Drug: peg‐IFN‐alpha/RBV treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peg‐IFN‐alpha/RBV treatment
Trial: 12733733
Drug: Alendronate, 10
RxNorm normalized name: Alendronate, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate, 10 mg/day plus calcium carbonate (600 mg daily)
Trial: 12733733
Drug: Simple vitamin
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple vitamin D (ergocalciferol, 30,000 IU weekly) plus calcium carbonate (600 mg daily)
Trial: 11642080
Drug: Amlodipine (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5-10 mg once a day)
Trial: 10100105
Drug: Perindopril (4-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4-8 mg once a day)
Trial: 1725545
Drug: Diltiazem controlled-release
RxNorm normalized name: diltiazem Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem controlled-release (CR) 120 mg b.i.d.
Trial: 6861770
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg b.i.d.
Trial: 6401458
Drug: Concurrent hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent hormone treatment and cytotoxic chemotherapy
Trial: 6401458
Drug: Sequential hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential hormone treatment and cytotoxic chemotherapy
Trial: 6401458
Drug: Sequential hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential hormone treatment for postmenopausal women in the low-risk category
Trial: 26897450
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (ST) for anxiety alleviation with anxiolytics
Trial: 24814272
Drug: Autologous periorbital
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous periorbital fat injections
Trial: 7664861
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (80 micrograms) and sodium cromoglycate (20 mg) combined
Trial: 10575337
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (20 mg)
Trial: 2708725
Drug: L-tryptophan supplementation
RxNorm normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-tryptophan supplementation and dietary manipulation
Trial: 935836
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets for 4-6 months (Control group)
Trial: 22998340
Drug: Sugar-free, artificially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar-free, artificially sweetened beverage (250 ml per day)
Trial: 22998340
Drug: Sugar-containing beverage
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar-containing beverage (250 ml per day providing 104 kcal)
Trial: 20634176
Drug: Colesevelam (3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam (3.75 g/d)
Trial: 18250617
Drug: Ghrelin administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ghrelin administration (1 microg/kg)
Trial: 11871738
Drug: Standard amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard amino acid solution (Vintène) for 10 days (Control group)
Trial: 11871738
Drug: Individualized amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized amino acid solution during the last 5 days (Experimental group)
Trial: 11871738
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received total parenteral nutrition for 10 days
Trial: 10502210
Drug: Enalapril 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 40 mg daily (E40)
Trial: 10502210
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg daily (E10)
Trial: 10502210
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg daily (E20)
Trial: 10502210
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg daily (E10)
Trial: 1702476
Drug: Single fraction
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single fraction radiation treatment (8, 10, 12, 15Gy)
Trial: 1702476
Drug: Multifraction dose
RxNorm normalized name: Titanium Dioxide 1.88 mg in 40 mL / OCTINOXATE 1.4 mg in 40 mL TOPICAL CREAM [Camellia Multiaction UV Sun Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifraction dose schedule (5Gy x 4, 5Gy x 5, 5Gy x 6)
Trial: 28810721
Drug: Low-dose sirolimus
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sirolimus (SRL) with extended-release tacrolimus (ER-TAC)
Trial: 28810721
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) with extended-release tacrolimus (ER-TAC)
Trial: 25391263
Drug: CRS followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CRS followed by HIPEC and then systemic chemotherapy (Group A)
Trial: 25391263
Drug: CRS only
RxNorm normalized name: CRS-207
DrugBank: CRS-207 (DB17323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRS only and systemic chemotherapy (Group B)
Trial: 16118355
Drug: Sham manipulative
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham manipulative treatment
Trial: 14643625
Drug: 12-week functional
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week functional exercise programme (40-min sessions, twice a week)
Trial: 18318773
Drug: Udenafil 100
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Udenafil 100 mg
Trial: 12297166
Drug: CRP>5mg/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP>5mg/l
Trial: 12297166
Drug: CRP<5mg/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP<5mg/l
Trial: 10078671
Drug: Neostigmine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (all doses)
Trial: 2158140
Drug: CY 222
RxNorm normalized name: Cys
DrugBank: Cysteine (DB00151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CY 222 (15,000 U AXa IC) administered via subcutaneous injection once daily for 14 days
Trial: 27632215
Drug: Dexamethasone intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone intravitreal implant (DEX implant) 0.7 mg every 5 months
Trial: 27632215
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg administered as per European Summary of Product Characteristics
Trial: 26337664
Drug: Dexamethasone intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone intravitreal implant (DEX implant)
Trial: 22293876
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg intravenously, twice daily for 5 days
Trial: 22293876
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg intravenously, twice daily for 5 days
Trial: 19059324
Drug: Novel fixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel fixed dose combination tablet containing 300mg zidovudine (AZT) and 160mg lamivudine (3TC)
Trial: 19059324
Drug: Duovir tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duovir tablet
Trial: 29959799
Drug: Jintrolong® 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jintrolong® 0.01 mg/kg
Trial: 29959799
Drug: Jintrolong® 0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jintrolong® 0.06 mg/kg
Trial: 29959799
Drug: Jintrolong® 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jintrolong® 0.2 mg/kg
Trial: 29959799
Drug: Jintrolong® 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jintrolong® 0.5 mg/kg
Trial: 29959799
Drug: Jintrolong® 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jintrolong® 0.8 mg/kg
Trial: 29959799
Drug: Conventional rhGH
RxNorm normalized name: rhGH
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional rhGH 0.067 mg/kg
Trial: 29959799
Drug: Jintrolong® 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jintrolong® 0.1 mg/kg
Trial: 29959799
Drug: Jintrolong® 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jintrolong® 0.4 mg/kg
Trial: 31695332
Drug: CoQ10 liquid
RxNorm normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CoQ10 liquid supplementation (100 mg/day for 3 months)
Trial: 29246188
Drug: Amoxicillin 750
RxNorm normalized name: amoxicillin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 750 mg orally three times a day for 100 days
Trial: 25029835
Drug: Pizhen treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pizhen treatment, once a week for 2 weeks (1 treatment course)
Trial: 22870676
Drug: Pizhen treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pizhen treatment
Trial: 19527383
Drug: Education with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education with pill count
Trial: 19527383
Drug: Pill count
RxNorm normalized name: Pill Counting Tray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill count alone
Trial: 9817625
Drug: Sertraline (50-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50-150 mg/day)
Trial: 6264825
Drug: Cl2MDP (1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cl2MDP (1600 mg daily for 12 weeks)
Trial: 31477359
Drug: Conventional Active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Active Drug Mixture (CADM)
Trial: 29030802
Drug: Stretta treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stretta treatment
Trial: 24913739
Drug: Facemask (FM)
RxNorm normalized name: FM-VP4
DrugBank: FM-VP4 (DB05449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facemask (FM) therapy
Trial: 24913739
Drug: Double-plate appliance/facemask
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-plate appliance/facemask (DPA-FM) therapy
Trial: 20102913
Drug: Triple antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol)
Trial: 14687046
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid 300 mg twice daily
Trial: 14687046
Drug: S-adenosyl-l-methionine 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-adenosyl-l-methionine 500 mg twice daily
Trial: 12452381
Drug: Intravenous atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous atropine before electroacupuncture
Trial: 9408704
Drug: Contraceptive vaginal
RxNorm normalized name: VCF 4% Contraceptive Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive vaginal ring (CVR) releasing 20 micrograms ethinyl estradiol and 1 mg of norethindrone acetate daily over two successive cycles with three different insertion regimens
Trial: 23383975
Drug: Saw palmetto
RxNorm normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saw palmetto (320 mg gelcap daily for 24 weeks, then 2 gelcaps daily for 24 weeks, then 3 gelcaps daily for 24 weeks)